长春瑞滨联合卡铂化疗治疗晚期肺癌的临床观察  

Effect of Chemotherapy on Tumor Markers Levels in Advanced Lung Cancer Patients

作　　者：缑剑 张永利 李王平[2] 李春梅[2] 翟梅 

机构地区：[1]陕西省咸阳市第一人民医院呼吸内科,陕西咸阳712000 [2]第四军医大学附属唐都医院呼吸内科,陕西西安710038

出　　处：《现代生物医学进展》2015年第25期4923-4925,4941,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金面上项目(81173610)

摘　　要：目的:探讨长春瑞滨联合卡铂化疗对晚期肺癌的治疗效果和安全性。方法:选取我院肿瘤科收治的晚期肺癌患者60例,根据不同治疗方案分为实验组与对照组,每组各30例患者。比较两组患者治疗前后的CEA、CA50、CYFRA21-1水平、白细胞计数及T淋巴细胞亚群CD4+、CD8+水平的变化。结果:治疗前,两组患者的CEA、CA50、CYFRA21-1水平、白细胞计数及T淋巴细胞亚群CD4+、CD8+水平比较均无统计学差异(P>0.05)。治疗后,实验组的CEA、CA50、CYFRA21-1、CD8+水平均明显低于对照组,而白细胞计数及T淋巴细胞亚群CD4+、CD4+/CD8+水平均显著高于对照组,差异均具有统计学意义(P<0.05)。结论:与放疗相比,长春瑞滨联合卡铂化疗能显著提高晚期肺癌的疗效,且不降低患者的细胞免疫。Objective： To investigate the clinical efficacy and safety of vinorelbine combined with carboplatin chemotherapy in the treatment of advanced lung cancer. Methods： 60 patients with advanced lung cancer were selected and randomly divided into the experimental group and control group according to different treatments, 30 cases in each group. The CEA, CA50, CYFRA21-1 levels,white blood cells count and T lymphocyte subsets CD4＋, CD8＋level were compared before and after treatment. Results： No statistically significant difference was found in the CEA, CA50, CYFRA21-1 levels, white blood cell count and T lymphocyte subsets CD4＋, CD8＋levels before treatment between two groups（P〉0.05）. Compared with the control group, the CEA, CA50, CYFRA21-1, CD8＋levels of experimental group were significantly lower after treatment（P〈0.05）, while the white blood cell count, CD4＋, CD4＋/CD8＋were significantly higher after treatment（P〈0.05）. Conclusion： Compared with radiotherapy, vinorelbine combined with carboplatin chemotherapy could significantly improve the clinical efficacy of advanced lung cancer and had no effect on the cellular immunity.

关 键 词：化疗 晚期肺癌 白细胞计数 细胞免疫 CEA CA50 CYFRA21-1 

分 类 号：R734.2[医药卫生—肿瘤]